Review Article
Toll-Like Receptor-Based Strategies for Cancer Immunotherapy
Table 2
Clinical studies on the application of TLR agonists for cancer treatment published since 2016.
| Target TLR | TLR agonist | Companion treatment | Conditions | Phase | Results | Reference |
| TLR2 | CADI-05 | Chemotherapy (cisplatin-paclitaxel) | Non-small-cell lung cancer | II | No survival benefit was observed with the addition of CADI-05 to chemotherapy. | [143] | TLR3 | Poly-ICLC | NY-ESO-1 peptide vaccine | Melanoma | I/II | Enhanced specific CD8+ T cell response. | [138] | Peptide-pulsed DCs | Pancreatic cancer | I | The treatment was safe and induced a measurable tumor-specific T cell population. | [142] | TLR3, TLR4 | Poly-ICLC, LPS | Multipeptide vaccine and incomplete Freund’s adjuvant | Melanoma | I | Combinations of poly-ICLC or LPS with peptide vaccine and incomplete Freund’s adjuvant are safe and induce T cell response. | [99] | TLR4 TLR9 | AS15 | Recombinant MAGE-A3 vaccine | Melanoma | I | The treatment was tolerated and produced durable Ab responses. | [139] | TLR7 | Imiquimod | Chemotherapy (paclitaxel) | Breast cancer cutaneous metastases | II | The combination was effective in inducing disease regression, but responses were short-lived. | [144] | TLR8 | Motolimod | Anti-EGFR (cetuximab) | Head and neck squamous cell carcinoma | I | The addition of TLR agonist enhanced the cellular antitumor immune response. | [140, 141] | TLR9 | GNKG168 | N/A | Minimal residual disease positive acute leukemia | I | Immunologic changes were observed. | [145] |
|
|